Apr 2 |
Centogene receives Nasdaq non-compliance letter
|
Apr 2 |
CENTOGENE Receives Nasdaq Non-Compliance Notice
|
Feb 29 |
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
|
Feb 28 |
Centogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plunge
|
Feb 28 |
CENTOGENE Explores Strategic Alternatives
|
Feb 28 |
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
|
Jan 24 |
CENTOGENE Receives French Research Tax Credit Accreditation
|
Jan 23 |
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
|
Jan 18 |
Centogene says FY revenue is expected to be between €48.5 million €49.0 million
|
Jan 18 |
CENTOGENE Announces Preliminary Full Year 2023 Revenue
|